DVA
DAVITA INC.Evidence as of 2026-09-26The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on DVA
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
Overview · DAVITA INC.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-pre…
Management team
- Mr. Kenneth Gardner Smith · Chief People OfficerFind on LinkedIn
- Mr. Misha Palecek · Chief Transformation Officer of U.S. Kidney Care BusinessFind on LinkedIn
- Mr. Jim Gustafson · Vice President of Investor RelationsFind on LinkedIn
- Mr. Javier J. Rodriguez · CEO & Executive DirectorFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it, not a rating or a recommendation.
+0.7 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled. The rest of the page is the evidence behind it.
The surviving record is constructive (+0.7 of a possible +2; was +0.7 before debate) with high confidence. Reported revenues rose from $ 3,223,529,000 in fiscal Q1 2025 (fiscal quarter ended 2025-05-09) to $ 3,554,084,000 in fiscal Q2 2026 (fiscal quarter ended 2026-07-31). Operating income increased from $ 438,937,000 in fiscal Q1 2025 to $ 579,001,000 in fiscal Q2 2026, equal to about 16.3% of revenue for that quarter. Net income and diluted EPS also expanded over the same span, from $ 162,917,000 and $ 2.00 respectively in fiscal Q1 2025 to $ 265,397,000 and $ 4.02 in fiscal Q2 2026, with intermediate EPS readings of $ 2.87 in fiscal Q1 2026 (fiscal quarter ended 2026-05-05) and $ 2.04 in fiscal Q3 2025 (fiscal quarter ended 2025-10-28). Reported common shares outstanding declined from 80,000,000 in the FY 2025 10‑K (period end reported in the 10‑K) to 63,800,000 as of 2026-07-31.
The filings corroborate operational complexity and cost pressures: revenue and refund liability estimation is materially complex for roughly 200,500 U.S. patients, labor and union activity are cited as ongoing cost pressures, and payor‑mix, supply‑chain, and reimbursement risks are emphasized. Valuation signals are mixed: trailing twelve‑month FCF is $ 314,565,000 (FCF per share TTM $ 4.7595) and Price‑to‑TTM‑FCF is 37.5, while EV/EBITDA (TTM) is 6.86 and P/E (TTM) is 15.51; the model implies an FCF growth rate of about 25.05% per year to justify today's price of $ 178.47, creating a tension between high implied growth and more moderate trailing multiples.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else (no outside knowledge, no browsing), so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC (revenue, margins, income, debt and share count, quarter by quarter) and reports which way the trend is running.
Reported revenues rose from $3,223,529,000 in the fiscal Q1 2025 (2025-01-01 to 2025-03-31, 3mo) to $3,554,084,000 in the fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo).
XBRL companyfacts · 0000927066-26-000108Operating income increased from $438,937,000 in the fiscal Q1 2025 (2025-01-01 to 2025-03-31, 3mo) to $579,001,000 in the fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo); the operating income reported for fiscal Q2 2026 represents about 16.3% of that quarter's revenue ($579,001,000 / $3,554,084,000).
XBRL companyfacts · 0000927066-26-000108Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full: its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet; its risk analysis fills in once that lands.
The company reported that determining primary and secondary coverage for approximately 200,500 U.S. patients at any point in time makes revenue and refund liability estimation materially complex.
10-K filed 2026-02-11The 10-K filed 11 February 2026 states that the business is labor intensive, that labor and staffing shortages (including a nursing shortage) and rising labor costs have continued to put pressure on the company's cost structure and could materially affect results.
10-K filed 2026-02-11Reads the signal panel above (momentum, volatility, drawdown, relative strength and beta) and ranks each against the whole research universe rather than judging it in isolation.
No computed signal history for this symbol yet — signals need roughly 70 trading days of price history.
Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
Institutional holders reported total holdings of $13.16B as of 2026-06-30, with 639 holders, a reported quarter-over-quarter value change of 118.4%, and a holder_count_delta_qoq of 410.
13F holdings · 639 filers · as of 2026-06-30Berkshire Hathaway Inc is reported as a top holder with $6.43B in holdings (reported quarter ended 2026-06-30).
13F holdings · 639 filers · as of 2026-06-30Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Multiple outlets reported intraday or recent share-price declines for DaVita, including a -4.62% move noted by one outlet on 24 Sept 2026 and a separate report of a 5.3% drop on 17 Sept 2026.
News · finance.yahoo.com · 2026-09-24Coverage flagged that DaVita underperformed the S&P 500 over the past three months in pieces focused on relative stock performance.
News · finance.yahoo.com · 2026-09-23Reads parsed Forms 3/4/5: who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No insider transactions on file in the trailing 180 days.
Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model-derived implied free cash flow (FCF) growth rate that today's price would justify is 25.05% per year.
Valuation inputs · SEC XBRL + stored EOD closePrice-to-TTM-FCF is 37.5, which implies the market price equals about 37.5 times the trailing twelve-month FCF.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score. The argument is shown, not hidden, so you can judge the reasoning yourself.
The cited fundamentals (rising revenues, operating income, net income and diluted EPS along with a material reduction in share count) together show improving per-share profitability and operational leverage in the reported periods; financial analysts and educators often view simultaneous top-line and margin expansion plus share count reduction as supportive of earnings quality. Large institutional ownership — notably a sizable stake reported for Berkshire Hathaway — signals meaningful investor confidence and increases the evidence weight on capital-market endorsement. While filings flag operational and reimbursement complexities and recent headlines note short-term share-price moves, those items describe risks and market noise rather than negating the documented improvement in operating margin (16.3% in Q2 2026) and the company’s positive trailing profitability multiples (EV/EBITDA 6.86, P/E 15.51). Observations about implied FCF growth versus trailing FCF multiples raise a valuation tension, but the contemporaneous earnings and cash-flow figures provide tangible evidence that supports a favorable read when focusing on reported operating and per-share performance.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.36
28 surviving claims rest on 12 distinct sources; the heaviest analyst carries 25% of them, and 100% of what the desk raised survived the debate.
The surviving read is supported by a moderate number of distinct sources but still rests on a limited evidence base: one analyst thread supplies a quarter of the claims and all desk-raised points survived internal debate, which raises the risk of confirmation bias. Source concentration and analyst dependence mean this read should be treated as informative but not definitive — its conclusions can shift if a few key documents or a single analyst’s inputs change.
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment. When the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here (no outside knowledge, no browsing), and each card shows who read it and what it contributed to the score.
13 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data, not retyped or estimated.
Read by Mercer+1.0 to the score
5 documents· 3 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes−1.0 to the score
3 holdings records· 1 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.8 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only; it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal; the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
The full terminal on DVA Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Get this for the names you actually hold
Every name in your portfolio, researched the same way, plus the one thing no sample can show: how each one sits inside what you already own.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.